The Association of Asian Pacific Community Health Organizations (AAPCHO), today launched new a website highlighting stories of Asian Americans and Pacific Islanders (AAPIs) impacted by hepatitis B.The #justB website was created to bring more attention to hepatitis B and the impac...
General News
Intern will work under the supervision of the Director of Program Implementation & Capacity Building in the NYC Department of Health, Viral Hepatitis Surveillance, Prevention & Control Program.
FDA Approves Viekira Pak to Treat Hep C A new hepatitis C medication, Viekira Pak, was approved today by the U.S. Food and Drug Administration (FDA). AbbVie, who markets the drug, has not immediately released the price of the new all-oral Hep C medication which will now rival Ha...
New York state’s Medicaid program spent $193.2 million during the first six months of 2014 on Sovaldi, the controversial Hepatitis C drug that carries an $84,000-per-patient price tag.
Olysio has been approved by the FDA, in combination with Sovaldi, for the treatment of Hepatitis C. It is substantially more expensive than Harvoni; although it depends on treatment time, a 12-week Harvoni treatment costs $94,500, compared to the Olysio-Sovaldi 12-week tag of $1...
Literature surrounding the burden of and factors associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in persons with tuberculosis (TB) disease remains limited and focused on populations outside the USA.
Seeking Personal Stories About Living With Hepatitis C Remedy Health Media, creator of the Live Bold Live Now initiative, works to empower patients and caregivers with the information and applications needed to efficiently navigate the healthcare landscape and as a result, to p...
“Have you been diagnosed with Hepatitis C? Are you a Baby Boomer – born between 1945 – 1965, and uncertain about your diagnosis? Do you write and understand English?”
Overview: CMS has finalized its decision to reimburse for HCV screening in primary care settings, for individuals who are Medicare eligible and either “high risk” or born between 1945-1965. “High risk” is defined as persons with a current or past history of illi...
On October 10, 2014, FDA approved HARVONI a fixed-dose combination tablet of ledipasvir 90 mg, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir 400 mg, an HCV nucleotide analog NS5B polymerase inhibitor. Harvoni is indicated for the treatment of chronic hepatitis C (CHC) ...
